Effects of intravenously administered recombinant vesicular stomatitis virus 
(VSV(deltaM51)) on multifocal and invasive gliomas

Lun, X; Senger, DL; Alain, T; Oprea, A; Parato, K; Stojdl, D; Lichty, B; Power, AT; Johnston , RN; Hamilton, M; Parney, I; Bell, JC; Forsyth, PA

doi:10.1093/jnci/djj413

アイテム詳細

登録内容を編集ファイル形式で保存

一時保存へ追加

タグ情報を表示リリース履歴を表示詳細要約

公開

学術論文

Effects of intravenously administered recombinant vesicular stomatitis virus (VSV(deltaM51)) on multifocal and invasive gliomas

MPS-Authors

There are no MPG-Authors in the publication available

External Resource

https://academic.oup.com/jnci/article/98/21/1546/2521872
(出版社版)

Fulltext (restricted access)

There are currently no full texts shared for your IP range.

フルテキスト (公開)

公開されているフルテキストはありません

付随資料 (公開)

There is no public supplementary material available

引用

Lun, X., Senger, D., Alain, T., Oprea, A., Parato, K., Stojdl, D., Lichty, B., Power, A., Johnston, R., Hamilton, M., Parney, I., Bell, J., & Forsyth, P. (2006). Effects of intravenously administered recombinant vesicular stomatitis virus (VSV(deltaM51)) on multifocal and invasive gliomas. Journal of the National Cancer Institute, 98(21), 1546-1557. doi:10.1093/jnci/djj413.

引用: https://hdl.handle.net/11858/00-001M-0000-0013-CF73-B

要旨

BACKGROUND:
An ideal virus for the treatment of cancer should have effective delivery into multiple sites within the tumor, evade immune responses, produce rapid viral replication, spread within the tumor, and infect multiple tumors. Vesicular stomatitis virus (VSV) has been shown to be an effective oncolytic virus in a variety of tumor models, and mutations in the matrix (M) protein enhance VSV's effectiveness in animal models.
METHODS:
We evaluated the susceptibility of 14 glioma cell lines to infection and killing by mutant strain VSV(deltaM51), which contains a single-amino acid deletion in the M protein. We also examined the activity and safety of this strain against the U87 and U118 experimental models of human malignant glioma in nude mice and analyzed the distribution of the virus in the brains of U87 tumor-bearing mice using fluorescence labeling. Finally, we examined the effect of VSV(deltaM51) on 15 primary human gliomas cultured from surgical specimens. All statistical tests were two-sided.
RESULTS:
All 14 glioma cell lines were susceptible to VSV(deltaM51) infection and killing. Intratumoral administration of VSV(deltaM51) produced marked regression of malignant gliomas in nude mice. When administered systemically, live VSV(deltaM51) virus, as compared with dead virus, statistically significantly prolonged survival of mice with unilateral U87 tumors (median survival: 113 versus 46 days, P = .0001) and bilateral U87 tumors (median survival: 73 versus 46 days, P = .0025). VSV(deltaM51) infected multifocal gliomas, invasive glioma cells that migrated beyond the main glioma, and all 15 primary human gliomas. There was no evidence of toxicity.
CONCLUSIONS:
Systemically delivered VSV(deltaM51) was an effective and safe oncolytic agent against laboratory models of multifocal and invasive malignant gliomas, the most challenging clinical manifestations of this disease.